Published online October 2, 2006
PEDIATRICS Vol. 118 No. 4 October 2006, pp. 1660-1663 (doi:10.1542/peds.2006-1182)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werlin, S. L.
Right arrow Articles by Fish, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werlin, S. L.
Right arrow Articles by Fish, D. L.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

The Spectrum of Valproic Acid–Associated Pancreatitis

Steven L. Werlin, MD and Daryl L. Fish, DO, MPH

Department of Pediatrics, Division of Gastroenterology, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, Wisconsin

OBJECTIVE. Our goal was to characterize valproic acid–associated pancreatitis in children.

PATIENTS AND METHODS. The charts of all patients with pancreatitis (diagnosed by using strict criteria) associated with valproic acid during a 10-year period were reviewed. Clinical and laboratory results were abstracted.

RESULTS. Twenty-two patients with valproic acid–associated pancreatitis were seen during the study period. Symptoms were similar to those of patients with pancreatitis from other etiologies and included abdominal pain/tenderness (83%), vomiting/retching (74%), abdominal distention (30%), and fever/chills (26%). Valproic acid levels were in the therapeutic range in all but 1 patient. The mean duration of therapy before the onset of pancreatitis was 32 months. The serum lipase level was >3 times the reference value in all patients, but the serum amylase level was not significantly elevated in 31% of the patients tested. Imaging studies altered clinical management in only 1 patient. The length of stay was generally brief (mean: 8 days). Two patients died. Of the 5 patients who were rechallenged, 4 had relapses.

CONCLUSIONS. Valproic acid–associated pancreatitis does not depend on valproic acid serum level and may occur any time after the onset of therapy. The serum lipase level is more sensitive than the serum amylase level and should be obtained when pancreatitis is suspected. Early imaging studies did not change clinical management. Rechallenge with valproic acid is dangerous and should be avoided.

Key Words: pancreatitis • valproic acid

Abbreviations: VPA—valproic acid • CT—computed tomography

Accepted May 23, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


eLetters:

Read all eLetters

Vaproate is an epigenetic modulator
Heikki Savolainen
Pediatrics Online, 5 Oct 2006 [Full text]